Home » Stocks » VIE

Viela Bio, Inc. (VIE)

Stock Price: $31.91 USD -0.81 (-2.48%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.75B
Revenue (ttm) 30.00M
Net Income (ttm) -139.61M
Shares Out 54.73M
EPS (ttm) -103.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $31.91
Previous Close $32.72
Change ($) -0.81
Change (%) -2.48%
Day's Open 32.32
Day's Range 30.70 - 33.37
Day's Volume 135,678
52-Week Range 19.60 - 70.66

More Stats

Market Cap 1.75B
Enterprise Value 1.32B
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 54.73M
Float 24.70M
EPS (basic) 76.44
EPS (diluted) -103.07
FCF / Share -2.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.80M
Short Ratio 17.89
Short % of Float 15.39%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 58.21
PB Ratio 3.99
Revenue 30.00M
Operating Income -143.86M
Net Income -139.61M
Free Cash Flow -138.29M
Net Cash 424.53M
Net Cash / Share 7.76
Gross Margin 166.67%
Operating Margin -479.55%
Profit Margin -465.40%
FCF Margin -460.97%
ROA -26.54%
ROE -45.41%
ROIC -86.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 5
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$60.50*
(89.60% upside)
Low
48.0
Current: $31.91
High
75.0
Target: 60.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue50.00-
Gross Profit50.00-
Operating Income-89.69-192
Net Income-86.43-190
Shares Outstanding12.31-
Earnings Per Share-7.02-19,027,000.00
Operating Cash Flow-105-29.53
Capital Expenditures-1.10-0.49
Free Cash Flow-106-30.02
Cash & Equivalents315127
Net Cash / Debt315127
Assets384140
Liabilities29.54328
Book Value355-188
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Viela Bio, Inc.
Country United States
Employees 152
CEO Zheng Bin Yao

Stock Information

Ticker Symbol VIE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VIE
IPO Date October 3, 2019

Description

Viela Bio, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.